Literature DB >> 2446065

Classification of serotonin receptors.

M Göthert1, E Schlicker.   

Abstract

The subdivision of serotonin (5-HT) receptors into three classes, designated 5-HT1, 5-HT2, and 5-HT3, has been based on radioligand binding studies and experiments in isolated tissues. As a result of radioligand binding studies, two types of 5-HT recognition sites have been postulated. One site specifically labeled by [3H]5-HT was termed 5-HT1, and the other one labeled by [3H]spiperone or [3H]ketanserin was designated 5-HT2. The pharmacological properties of the latter sites are obviously identical to those of the majority of the classical "D" receptors, whereas a smaller proportion of "D" receptors resemble the 5-HT1 type. Hence, according to the current definition, 5-HT1 and 5-HT2 receptors mediate effects previously ascribed to "D" receptors. Three subtypes of 5-HT1 binding sites, designated 5-HT1A, 5-HT1B, and 5-HT1C, can now be distinguished by improved binding assay with rather selective radioligands. The identity of a given 5-HT binding site with a 5-HT receptor was suggested by correlating the agonists' and antagonists' affinities for the binding site with their potencies to produce certain effects. This was further confirmed by the development of rather selective agonists and antagonists. A third class of 5-HT receptors, the "M" receptors, which are now designated 5-HT3 in order to distinguish them from muscarinic cholinoceptors, were identified in functional in vitro experiments. They are present on terminals of sympathetic and parasympathetic nerves and on afferent nerve fibers. All three receptor classes are involved in cardiovascular regulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446065

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

Review 1.  The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

2.  Characterization of an endothelial 5-hydroxytryptamine (5-HT) receptor mediating relaxation of the porcine coronary artery.

Authors:  G J Molderings; G Engel; E Roth; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

3.  Brain serotonergic circuitries.

Authors:  Yves Charnay; Lucienne Léger
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

4.  Inhibition of N-methyl-D-aspartate (NMDA)- and L-glutamate-induced noradrenaline and acetylcholine release in the rat brain by ethanol.

Authors:  M Göthert; K Fink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-11       Impact factor: 3.000

5.  Effect of ketanserin, a selective antiserotoninergic drug, on human anal canal pressure.

Authors:  M Neri; L Marzio; C De Angelis; O Pieramico; A Mezzetti; F Cuccurullo
Journal:  Int J Colorectal Dis       Date:  1988-11       Impact factor: 2.571

Review 6.  The role of serotonin in cardiovascular diseases and their treatment.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

7.  Effects of GTP, forskolin, sodium fluoride, serotonin, dopamine, and carbachol on adenylate cyclase in Teleost retina.

Authors:  N N Osborne
Journal:  Neurochem Res       Date:  1990-05       Impact factor: 3.996

8.  Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava.

Authors:  G J Molderings; K Fink; E Schlicker; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

9.  Identification of presynaptic 5-HT1 autoreceptors in pig brain cortex synaptosomes and slices.

Authors:  K Fink; E Schlicker; R Betz; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

10.  Naftopidil inhibits 5-hydroxytryptamine-induced platelet aggregation and 5-hydroxytryptamine uptake in platelets of healthy volunteers.

Authors:  R Kirsten; M Breidert; K Nelson; A Heine; S Rosenkranz; B Erdeg; G Niebch; H O Borbe; M Siebert-Weigel; J Respondek
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.